FARMACIA HOSPITALARIA最新文献

{"title":"Complications associated with parenteral nutrition in hospitalized patients.","authors":"María Susana Fortes González, Eva María Menor Fernández, Silvia Vázquez Blanco, Susana Castro Luaces, Claudia Barca Díez, Leticia Herrero Poch, Natividad Lago Rivero, Lara Martínez Domínguez, Ruth Boente Varela, Noemí Martínez López de Castro","doi":"10.1016/j.farma.2026.07.004","DOIUrl":"https://doi.org/10.1016/j.farma.2026.07.004","url":null,"abstract":"<p><strong>Objective: </strong>Malnutrition is common in hospitalized patients. Parenteral nutrition is a therapeutic alternative to meet the nutritional requirements of patients in whom the gastrointestinal tract is unavailable or non-functional. This therapy has been associated with a wide range of infectious, mechanical and metabolic complications. The aim of the study was to assess the incidence of these complications.</p><p><strong>Method: </strong>A prospective multicenter observational study in hospitalized adult patients receiving parenteral nutrition ≥72 h was conducted. Follow-up was performed until one week after the discontinuation of parenteral nutrition. Data were collected from electronic medical records and parenteral nutrition validation programs (Kabisoft and Clinus). Risk of malnutrition was determined according to MUST or CONUT criteria. The main variables were: incidence of catheter-related bacteriemia, catheter-tip colonization, phlebitis, thrombosis, catheter obstruction, catheter malposition, pneumothorax, hyperglycemia, hypertriglyceridemia, hypercholesterolemia, hepatobiliary disorders and refeeding syndrome. A descriptive analysis was performed using SPSS v23 software.</p><p><strong>Results: </strong>Sixty patients were included, with a median age of 68 (28-90) years, 48.3% men and a body mass index of 26.2 ± 6.6 kg/m². Of these, 61.7% were surgical patients and 46.7% were at low risk of malnutrition. Parenteral nutrition was administered for a median of 10 (3-40) days, 90.0% through central access. Patients received a mean of 18.4 ± 5.0 kcal/kg/day (74.7% of requirements), 1.1 ± 0.4 g/kg/day of protein, 2.4 ± 0.7 g/kg/day of glucose, and 0.5 ± 0.2 g/kg/day of lipids. Of them, 35% received concomitant enteral nutrition. Overall, 80.0% experienced at least one complication: metabolic (71.7%), mechanical (18.3%), and infectious (10.0%). Incidences were: hepatobiliary alteration (61.7%), hyperglycemia (48.3%), phlebitis (13.3%), catheter occlusion (8.3%), catheter-related bacteriemia (8.3%), hypertriglyceridemia (1.7%), hypercholesterolemia (1.7%), and colonization (1.7%). Gram-positive microorganisms were the most frequently isolated.</p><p><strong>Conclusions: </strong>Although complications associated with parenteral nutrition occur, the rate of serious complications, such as infections, is low. While most patients experienced at least one complication, metabolic events were the most common, and they are generally ease to detect and manage. The incidence of mechanical complications, mainly phlebitis and catheter occlusions, was moderate.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148714155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Guideline to radiopharmaceutical procedures for in vitro labeling of leukocytes.","authors":"Inmaculada Romero-Zayas, María de Arcocha-Torres, Iván Peñuelas, Elena Martínez Montalbán, María Carmen Plancha Mansanet, Antonio de Jesús Fernández Sánchez, Juan Antonio Pérez Iruela","doi":"10.1016/j.farma.2026.07.006","DOIUrl":"https://doi.org/10.1016/j.farma.2026.07.006","url":null,"abstract":"<p><p>This guide outlines the radiopharmaceutical procedure for the in vitro labelling of leukocytes. Scintigraphy using leukocytes labeled with [^99mTc]Tc-exametazime or [¹¹¹In]In-oxine is a highly valuable diagnostic tool in infectious and inflammatory diseases due to its high sensitivity and specificity. It is based on established guidelines and consensus protocols, which incorporate the recent Spanish regulations on the extemporaneous preparation of radiopharmaceuticals, this document provides detailed and precise instructions for the safe and effective preparation and quality control of in vitro labeled leukocytes. The clinical indications for leukocyte scintigraphy are described, along with the technical requirements for both facilities and equipment. The various stages of the radiolabelling procedure are developed and substantiated, including blood sample collection, leukocyte fraction separation and isolation, incubation and subsequent radiolabelling with either [^99mTc]Tc-exametazime or [¹¹¹In]In-oxine, radiopharmaceutical conditioning for administration, and the necessary quality control procedures. The document concludes with a section describing drug interactions reported in the literature. Two annexes are included, providing example labeling protocols for both radiopharmaceuticals.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148714099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants of adherence to calcium/vitamin D supplements in a cross-sectional study.","authors":"Daniel Gómez-Costas, Ana de Lorenzo-Pinto, Covadonga Iznaola-Muñoz, Anaís Carrillo-Burdallo, Yeray Rioja-Díez, María Martín-Bartolomé, Ana Herranz-Alonso, María Sanjurjo-Sáez","doi":"10.1016/j.farma.2026.06.011","DOIUrl":"https://doi.org/10.1016/j.farma.2026.06.011","url":null,"abstract":"<p><strong>Objective: </strong>Adherence to combined calcium and vitamin D supplements is often suboptimal, yet the independent role of formulation attributes (pharmaceutical form, organoleptic profile, acceptability) remains understudied. The aim was to estimate Calcium/Vitamin D adherence in real-world practice and to identify associated factors, with particular emphasis on formulation characteristics and patient-perceived acceptability.</p><p><strong>Methods: </strong>Population-based analytical cross-sectional study (STROBE guidelines). Random telephone interviews were conducted with 360 participants from a tertiary hospital catchment area in Madrid, with active prescriptions for over 6 months, complementing the data with electronic dispensing records. Global adherence was defined as the simultaneous fulfillment of: self-reported adherence >90%, a Morisky-Green result compatible with adherence, and ≥90% of expected dispensations in the previous 6 months. Formulations were classified a priori into five organoleptic groups based on their sweetener and flavor profile. Acceptability was assessed using 1-5 Likert scales for taste, texture, and overall rating. Univariate and multivariable logistic regression were used to identify factors associated with adherence.</p><p><strong>Results: </strong>Twenty-two different formulations were identified. Global adherence was 34.7% (95% CI: 30.0-39.8). Agreement between measures was moderate (κ = 0.38-0.60). Self-reporting (70.8%) significantly overestimated adherence compared to dispensing records (40.3%). Chewable tablets showed higher adherence than orodispersible and effervescent forms. In the multivariable model, adherence was independently associated with female sex (aOR 2.69; 95% CI: 1.59-4.59), polypharmacy (>10 drugs) (aOR 2.32; 95% CI: 1.32-4.07), polyol-based organoleptic group (aOR 2.43; 95% CI: 1.26-4.77) and overall rating of 5/5 (aOR 6.17; 95% CI: 3.16-12.50). Adverse reactions (reported by 15.3% of participants) reduced the probability of adherence (aOR 0.24; 95% CI: 0.08-0.58). Forgetfulness was the main reason for non-adherence (63.8%), followed by organoleptic problems and intolerance. The model showed good discrimination (Area under the curve 0.83).</p><p><strong>Conclusions: </strong>Strict adherence to calcium/vitamin D is low, and self-reporting substantially overestimates actual compliance. Beyond classical patient-level factors, formulation tolerability and acceptability emerge as independent, potentially modifiable determinants of adherence. A simple screening strategy based on patient overall rating, adverse reactions and formulation organoleptic profile could guide early, pragmatic interventions such as adherence support and timely formulation switching.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148680369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemical stability and physical compatibility of frozen vancomycin oral solution.","authors":"Víctor Martínez-Toledo, María Amparo Martínez-Gómez, Daniel Viedma-Rama, Jesús López-Jiménez, Paula Bárcena-Salgado, Ana Cristina Cercós-Lletí, Mónica Climente-Martí","doi":"10.1016/j.farma.2026.06.004","DOIUrl":"https://doi.org/10.1016/j.farma.2026.06.004","url":null,"abstract":"<p><strong>Objective: </strong>Oral vancomycin is a first-line treatment for Clostridioides difficile infection. When used as an oral solution, its beyond-use date is limited to 14 days in an opened container and at 2-8 °C, according to the guidelines set out in the Guide to Good Preparation Practices for Medicines in Hospital Pharmacy Services. This complicates batch preparation in order to meet the increasing demand for this medication. This study evaluated the physicochemical stability of vancomycin hydrochloride in oral solution under freezing and subsequent thawing conditions.</p><p><strong>Method: </strong>An oral solution of vancomycin hydrochloride was prepared at a concentration of 12.5 mg/mL, and aliquots were packaged in two types of containers (transparent polypropylene cup and amber polyethylene terephthalate bottle). The aliquots were frozen at -25 °C. After 1, 7, 14, 21, 35, 60, 88, and 123 days, they were thawed and then stored at 2-8 °C for 14 days. Residual concentration was determined using an Agilent Technologies 1100 HPLC system (at t = 0, 3, 6, 10, and 14 days after thawing), and physical compatibility was assessed by pH measurement using a pH meter (model 3510, Jenway, UK) with a glass electrode, as well as by visual inspection.</p><p><strong>Results: </strong>The residual concentration of vancomycin hydrochloride remained ≥91.9% of its initial concentration (12.5 mg/mL) for up to 123 days under frozen storage (-25 °C) and after 14 days under refrigeration (2-8 °C). The pH variation was ≤ ± 0,18, and no changes in color, turbidity, or precipitate formation were detected in any of the aliquots.</p><p><strong>Conclusions: </strong>Vancomycin hydrochloride oral solution at a concentration of 12.5 mg/mL maintains its physicochemical stability for up to 123 days under frozen storage and after thawing followed by storage for 14 days at 2-8 °C, regardless of photoprotection.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148621934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Cost-effectiveness of immune checkpoint inhibitors for non-small cell lung cancer in a third level hospital.","authors":"Ana Álvarez-Yuste, María Pérez-Abánades, Ramón Colomer-Bosch, Irene Cuadrado-Berrocal, Jacobo Rogado-Revuelta, Tomás Gallego-Aranda, Ainhoa Aranguren-Oyarzábal","doi":"10.1016/j.farma.2026.04.017","DOIUrl":"https://doi.org/10.1016/j.farma.2026.04.017","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the effectiveness and cost-effectiveness of immune checkpoint inhibitors in patients with non-small cell lung cancer (NSCLC) in real-world clinical practice.</p><p><strong>Methods: </strong>A retrospective, single-center observational study including NSCLC patients treated with atezolizumab, durvalumab, nivolumab, and pembrolizumab between 2015 and 2023. Demographic, clinical, and treatment data, as well as adverse events, were recorded. Statistical analysis was performed using the R Core Team (2024) software.</p><p><strong>Results: </strong>In stage IV, pembrolizumab demonstrated the longest median overall survival (OS) at 15.49 months, compared to nivolumab (10.26 months) and atezolizumab (9.24 months). In stage III, pembrolizumab reached an OS median of 34.64 months, nivolumab 17.03 months, and atezolizumab 10.62 months. Durvalumab reached an OS median of 30.18 months. In stage IV, the Incremental Cost-Effectiveness Ratio (ICER) of pembrolizumab versus atezolizumab was €517.92 per month of life gained, and the ICER of pembrolizumab versus nivolumab was €512.66 per month of life gained. In stage III with palliative intent, the ICER of pembrolizumab versus atezolizumab was €135.76 per month of life gained, and the ICER of pembrolizumab versus nivolumab was €152.26 per month of life gained.</p><p><strong>Conclusions: </strong>Although real-world survival outcomes are lower than those reported in pivotal clinical trials, immunotherapy is established as an efficient strategy for the National Health System. All analyzed drugs were cost-effective in the hospital setting studied, falling below the efficiency thresholds proposed by the WHO for Spain (<€65,180/year). The sustainability of these high-budget-impact treatments depends on precise patient selection based on biomarkers and the implementation of dosage optimization strategies. There is a need for local economic evaluations to guide clinical and management decision-making.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148608429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review and adjusted indirect comparison of first-line immune checkpoint inhibitors in metastatic colorectal cancer.","authors":"Y Reyes-de-la-Mata, S Fenix-Caballero, F J Salmeron-Navas","doi":"10.1016/j.farma.2026.06.008","DOIUrl":"https://doi.org/10.1016/j.farma.2026.06.008","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the efficacy and safety of immune checkpoint inhibitors in the first-line treatment of microsatellite instability or mismatch repair-deficient metastatic colorectal cancer through a systematic review and adjusted indirect comparison, determining whether they are equivalent therapeutic alternatives.</p><p><strong>Methods: </strong>A systematic literature search was conducted in PubMed and Embase following PRISMA 2020 recommendations. Phase III randomized controlled trials evaluating immune checkpoint inhibitors in microsatellite instability or mismatch repair-deficient metastatic colorectal cancer were eligible. Efficacy was assessed using Bucher's adjusted indirect comparison method, with progression-free survival as the primary endpoint. Therapeutic equivalence was evaluated according to the Equivalent Therapeutic Alternatives framework, applying a non-inferiority margin (Δ) of 0.65. Safety outcomes included overall and treatment-related adverse events, immune-related adverse events, discontinuations due to adverse events and grade 5 events.</p><p><strong>Results: </strong>NI demonstrated a higher probability of superior efficacy over pembrolizumab, with an adjusted Hazard Ratio of 0.53 (95%CI 0.34 to 0.84) for progression-free survival, exceeding the equivalence margin. Thus, pembrolizumab and nivolumab+ipilimumab cannot be considered Equivalent Therapeutic Alternatives regarding efficacy. In terms of safety, nivolumab+ipilimumab was associated with fewer treatment-related grade ≥ 3 adverse events but higher rates of treatment discontinuation and immune-related adverse events compared to pembrolizumab.</p><p><strong>Discussion: </strong>Nivolumab+ipilimumab appears to offer greater efficacy than pembrolizumab in first-line treatment of microsatellite instability or mismatch repair-deficient metastatic colorectal cancer, but with a distinct safety profile. Based on current interim data, these agents should not be regarded as equivalent therapeutic alternatives. Further data, including final efficacy analyses and quality-of-life assessments, are warranted to guide optimal treatment selection.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148550819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Listening to transform: Impact of patient experience on the improvement of an outpatient pharmacy unit.","authors":"Silvia Vázquez-Gómez, Susana Castro-Luaces, Leticia Herrero-Poch, Mónica Gayoso-Rey, David Rodríguez-Lorenzo, Mercedes Freire-González, Noemí Martínez-López de Castro","doi":"10.1016/j.farma.2026.05.007","DOIUrl":"https://doi.org/10.1016/j.farma.2026.05.007","url":null,"abstract":"<p><strong>Objective: </strong>Patient experience is currently recognised as one of the pillars of healthcare quality and a key tool for guiding organisational improvement. This study aimed to evaluate how the systematic collection of patient experience through surveys, integrated into a Quality Management System (QMS), can drive improvement interventions in pharmaceutical care for outpatients attending a Hospital Pharmacy Service (HPS).</p><p><strong>Methods: </strong>An observational, descriptive and retrospective study based on repeated annual cross-sectional patient experience surveys was conducted between 2023 and 2025 among outpatients treated at the HPS of a tertiary hospital. The questionnaire assessed patient experience across four thematic domains: facilities, organisation, pharmaceutical consultation and overall satisfaction. Items were rated using a five-point Likert scale, and open-ended fields were included to collect qualitative comments. The surveys were distributed electronically via the Galician Health Service platform. The results were integrated into the PIC/EM continuous improvement cycle (Plan, Implement, Control/Evaluate and Improve) within a QMS certified according to ISO 9001:2015.</p><p><strong>Results: </strong>A total of 15,056 surveys were distributed, and 3,175 responses were obtained, yielding a response rate of 21.1%. Overall satisfaction with the HPS remained high and stable throughout the study period, with mean scores of 4.30 for in-person care and 4.38 for remote care, both exceeding the overall hospital rating. Interaction with the pharmacist, including professional treatment, clarity of information and time devoted to the consultation, was the most highly rated aspect. Survey analysis identified areas for improvement related to telephone communication, appointment management and certain organisational aspects. These findings were used as a strategic input for the QMS to implement interventions aimed at improving accessibility, communication and the humanisation of care.</p><p><strong>Conclusions: </strong>The integration of PREMs into an ISO 9001:2015-certified QMS strengthened patient-centred care by transforming the users' voice, through the PIC/EM cycle, into specific improvement actions, including FarmaLink. The HPS achieved a high satisfaction score, 4.32, which was higher than the hospital average. This co-design model may help optimise strategic resources; future research should assess its actual impact on adherence, clinical outcomes and continuity of care.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148425374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MAPEX-SEFH guide for the implementation of patient-reported outcomes and experience in outpatient hospital pharmacy.","authors":"Gabriel Mercadal Orfila, Roberto Collado Borrell, Luis Margusino Framiñan, Ramón Morillo-Verdugo","doi":"10.1016/j.farma.2026.05.008","DOIUrl":"https://doi.org/10.1016/j.farma.2026.05.008","url":null,"abstract":"<p><p>The integration of patient-reported outcomes (PROMs) and patient-reported experience measures (PREMs) represents a key step toward value-based pharmaceutical care in outpatient hospital pharmacy settings. The MAPEX guideline for the implementation and use of PROMs and PREMs provides a practical framework for their integration into clinical practice, aligned with the Capacity-Motivation-Opportunity (CMO) model. This work synthesizes its main components from an applied perspective, combining available evidence with the strategic principles of the MAPEX project and prioritizing real-world applicability. The guideline proposes a structured and pragmatic approach to the implementation of PROMs and PREMs, linking their use to patient stratification, motivational interviewing, and longitudinal follow-up through dual care models combining face-to-face and digital interventions. It defines criteria for instrument selection, clinical interpretation of results, and the technological and organizational requirements for implementation, as well as key barriers and facilitators. In this context, PROMs and PREMs are positioned as actionable tools that support clinical decision-making, enable personalized pharmacotherapeutic follow-up, and make the impact of pharmaceutical care visible through patient-relevant outcomes. The integration of these instruments within the MAPEX-CMO framework reinforces person-centered, value-based care models and supports a more efficient, personalized, and clinically meaningful approach. Their implementation contributes to consolidating the role of hospital pharmacists in the evaluation of health outcomes and the improvement of patient experience.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148406184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concordance between the theoretical and real stratification of the ability-motivation-opportunity model in patients with cardiovascular pathologies.","authors":"Cecilia Solís-Martín, Ramón Morillo-Verdugo","doi":"10.1016/j.farma.2026.06.006","DOIUrl":"https://doi.org/10.1016/j.farma.2026.06.006","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the concordance between the stratification offered by the tool included in the adaptation of the capability-motivation-opportunity model for patients with cardiovascular diseases developed by De Dios et al. 2025 and that obtained when applying it in clinical practice.</p><p><strong>Methods: </strong>Observational, cross-sectional, single-center study (January-March 2025) which included patients undergoing active treatment with proprotein convertase subtilisin/kexin type 9 inhibitors or inclisiran who attended outpatient hospital pharmacy consultations. The variables collected for stratification were demographic, clinical, pharmacotherapeutic, and socio-health variables. The adapted capacity-motivation-opportunity model in patients with cardiovascular diseases was used for stratification. The Chi-square method for a single sample was used to analyze concordance. The data were processed using the IBM-SPSS v.30 statistical program.</p><p><strong>Results: </strong>A total of 126 patients were included (median age 63.2 years (IQR = 58.9-72.5); 69.2% men). The percentages obtained were 6.3% (95% CI: 2.1-10.6%) in priority 1, 33.3% (95% CI: 25.1-41.6%) in priority 2, and 60.3% (95% CI: 51.8-68.8%) in priority 3, with theoretical distribution being 10, 30, and 60%, respectively (p = 0.342).</p><p><strong>Conclusion: </strong>There is agreement between both distributions, which supports the applicability of the tool in healthcare practice, and it can be used to prioritize resources in outpatient consultations.</p>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148399542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tuberculosis extrapulmonar multirresistente en un paciente en hemodiálisis tratado con bedaquilina y tedizolid. Presentación de un caso y revisión de la literatura","authors":"Paula Novo González,&nbsp;Irene Galindo Marín,&nbsp;Elena García Benayas,&nbsp;Carmen Mon Mon,&nbsp;Rafael Torres Perea,&nbsp;Sara Hernández Egido","doi":"10.1016/j.farma.2025.07.008","DOIUrl":"10.1016/j.farma.2025.07.008","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 285-287"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145582609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}